Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 in recurrent or metastatic gynecological malignancies and solid tumors
NCT05803018Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in gynecological malignancies, solid tumor, sponsored by Biokin Pharmaceutical. Started Jun 2023; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
gynecological malignanciessolid tumor
Beyond the preview
Go deeper on NCT05803018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803018.